Ipsen To File Cabozantinib For Liver Cancer In 1H 2018

16 Oct 2017

• By Lucie Ellis-Taitt

Exelixis and Ipsen's Phase III CELESTIAL trial succeeds: cabozantinib meets primary overall survival endpoint in patients with advanced liver cancer.

Cirrhosis — Ipsen to file cabozantinib for liver cancer in Europe after Positive Phase III

More from Anticancer

More from Therapy Areas